Literature DB >> 12529677

Qualitative and quantitative analysis of human herpesviruses in chronic and acute B cell lymphocytic leukemia and in multiple myeloma.

S Hermouet1, C A Sutton, T M Rose, R J Greenblatt, I Corre, R Garand, A M Neves, R Bataille, J W Casey.   

Abstract

Real-time quantitative polymerase chain reaction (qPCR) was used to quantify viral loads of human herpesviruses (HHVs) at diagnosis in 61 samples of malignant B cells: 21 chronic lymphocytic leukemia (B-CLL), 29 acute lymphoblastic leukemia (B-ALL) and 11 multiple myeloma (MM); control samples were blasts from 16 acute myeloid leukemia (AML) and 24 blood or bone marrow samples from healthy donors. The majority of samples from healthy donors and patients (B-ALL, B-CLL or AML, but not MM) was positive for EBV and contained <100 ebv copies/100 ng dna. ebv loads were occasionally high (>500 copies/100 ng DNA) in B-ALL (2/16) and in B-CLL (2/21) samples. The fractions of samples positive for HHV-8 and HHV-6A, less than 10% for MM patients, were high for adults with B-ALL (18.8% HHV-8+, 43.8% HHV-6A+) or B-CLL (28.6% HHV-8+, 52.4% HHV-6A+). B-ALL, B-CLL and MM samples were rarely positive for HHV-6B and HHV-7. Lastly, 75% of B-ALL samples were positive for CMV, and CMV loads were significantly higher in B-ALL samples than in MM, B-CLL or AML samples. We also used PCR with consensus-degenerate hybrid oligonucleotide primers (CODEHOP) to look for novel HHVs in B cell samples: no sequence indicative of a new HHV was detected. Altogether, the data indicate that the presence of multiple HHVs, including EBV and CMV at high loads, is not rare in B-ALL and B-CLL cell samples. Future prospective studies should determine whether patients with high EBV/CMV loads at diagnosis in tumor samples face a higher risk of delayed hematological recovery, virus-related complications or relapse.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12529677     DOI: 10.1038/sj.leu.2402748

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  15 in total

1.  Graft versus leukemia response without graft-versus-host disease elicited by adoptively transferred multivirus-specific T-cells.

Authors:  Jan J Melenhorst; Paul Castillo; Patrick J Hanley; Michael D Keller; Robert A Krance; Judith Margolin; Ann M Leen; Helen E Heslop; A John Barrett; Cliona M Rooney; Catherine M Bollard
Journal:  Mol Ther       Date:  2014-09-30       Impact factor: 11.454

2.  Infection as a cause of childhood leukemia: virus detection employing whole genome sequencing.

Authors:  Christoph Bartenhagen; Ute Fischer; Klaus Korn; Stefan M Pfister; Michael Gombert; Cai Chen; Vera Okpanyi; Julia Hauer; Anna Rinaldi; Jean-Pierre Bourquin; Cornelia Eckert; Jianda Hu; Armin Ensser; Martin Dugas; Arndt Borkhardt
Journal:  Haematologica       Date:  2017-02-02       Impact factor: 9.941

3.  In utero cytomegalovirus infection and development of childhood acute lymphoblastic leukemia.

Authors:  Stephen Starko Francis; Amelia D Wallace; George A Wendt; Linlin Li; Fenyong Liu; Lee W Riley; Scott Kogan; Kyle M Walsh; Adam J de Smith; Gary V Dahl; Xiaomei Ma; Eric Delwart; Catherine Metayer; Joseph L Wiemels
Journal:  Blood       Date:  2016-12-15       Impact factor: 22.113

4.  Epidemiologic analysis of reactivated cytomegalovirus antigenemia in patients with cancer.

Authors:  Xiang Y Han
Journal:  J Clin Microbiol       Date:  2007-02-07       Impact factor: 5.948

5.  Principal component analysis uncovers cytomegalovirus-associated NK cell activation in Ph+ leukemia patients treated with dasatinib.

Authors:  K Ishiyama; T Kitawaki; N Sugimoto; T Sozu; N Anzai; M Okada; M Nohgawa; K Hatanaka; N Arima; T Ishikawa; S Tabata; T Onaka; S Oka; Y Nakabo; R Amakawa; M Matsui; T Moriguchi; A Takaori-Kondo; N Kadowaki
Journal:  Leukemia       Date:  2016-06-14       Impact factor: 11.528

6.  CMV reactivation is associated with a lower incidence of relapse after allo-SCT for CML.

Authors:  S Ito; P Pophali; Wu CO; E K Koklanaris; J Superata; G A Fahle; R Childs; M Battiwalla; A J Barrett
Journal:  Bone Marrow Transplant       Date:  2013-04-08       Impact factor: 5.483

7.  Monoclonal IgG in MGUS and multiple myeloma targets infectious pathogens.

Authors:  Adrien Bosseboeuf; Delphine Feron; Anne Tallet; Cédric Rossi; Cathy Charlier; Laurent Garderet; Denis Caillot; Philippe Moreau; Marina Cardó-Vila; Renata Pasqualini; Wadih Arap; Alfreda Destea Nelson; Bridget S Wilson; Hélène Perreault; Eric Piver; Pierre Weigel; François Girodon; Jean Harb; Edith Bigot-Corbel; Sylvie Hermouet
Journal:  JCI Insight       Date:  2017-10-05

8.  Clinical relevance of novel Otarine herpesvirus-3 in California sea lions (Zalophus californianus): lymphoma, esophageal ulcers, and strandings.

Authors:  Stephanie Venn-Watson; Celeste Benham; Frances M Gulland; Cynthia R Smith; Judy St Leger; Pam Yochem; Hendrik Nollens; Uriel Blas-Machado; Jeremiah Saliki; Katie Colegrove; James Fx Wellehan; Rebecca Rivera
Journal:  Vet Res       Date:  2012-12-12       Impact factor: 3.683

9.  Quantitative analysis of human herpesvirus-6 genome in blood and bone marrow samples from Tunisian patients with acute leukemia: a follow-up study.

Authors:  Nefzi Faten; Gautheret-Dejean Agnès; Ben Fredj Nadia; Abid Ben Salem Nabil; Zaier Monia; Khelif Abderrahim; Agut Henri; Feki Salma; Aouni Mahjoub
Journal:  Infect Agent Cancer       Date:  2012-11-12       Impact factor: 2.965

10.  Joint Nordic prospective study on human herpesvirus 8 and multiple myeloma risk.

Authors:  R Tedeschi; T Luostarinen; P De Paoli; R E Gislefoss; L Tenkanen; J Virtamo; P Koskela; G Hallmans; M Lehtinen; J Dillner
Journal:  Br J Cancer       Date:  2005-10-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.